ClinicalTrials.gg
RecruitingNCT04953767Updated Aug 30, 2023

The Circadian Rhythm of ICU Patients With Acute Myocardial Infraction and the Effect of Light Therapy

An interventional study of Blue light therapy and White light in Circadian Dysrhythmia and Delirium, sponsored by Chang Gung Memorial Hospital. Recruiting at 1 site in Taiwan. Open to participants aged 35 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-08-30.

Sponsored by Chang Gung Memorial Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2024, 2 years 2 months ago, but the record still lists the study as recruiting.
  • Started May 2021; still recruiting 5 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
35 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Delirium with a site in Taiwan — 5 open to participants now, 6 under way, none of them phase 3. Delirium · Taiwan.

Planned enrollment
9th of 11
70 · median 100
Started
2021
with 2 others
No phase
9 of 17
4 open now
Registered
6th of 17
by date
Lead sponsor
1 of 17
Chang Gung Memorial Hospital

Among the 17 studies in Delirium with a site in Taiwan, this one is the 9th largest by planned enrollment of the 11 interventional ones that give a count, is one of 3 that started in 2021, is one of 9 with no phase, and was the 6th registered.

Delirium

935 studies on the registry are indexed under Delirium; 188 are open to participants now.

Browse Delirium studies →

Open to participants now

5 of the 17 studies in Delirium with a site in Taiwan are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 124 Delirium studies recruiting now, 96 (77%) set no upper age limit and 8 (6%) stop at 75 or younger; 8 take children under 18; 14 take healthy volunteers.

This study: 35 Years to 85 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Delirium with a site in Taiwan, or all of them as a file.
02

Study summary

By using subjective and objective measurements, the investigators monitor the change of circadian rhythm in Intensive Care Unit (ICU) patients with acute myocardial infarction and the effect of light therapy.

Read the detailed description

The investigators include 70 patients who are admitted to coronary care unit due to coronary artery disease, with severity between Killip I-III and age between 35-85. Participants are randomly assigned to 2 groups, the experimental group (blue light) and the placebo group (white light). Both groups receive light therapy or white light daily between 8am to 12pm. The investigators use actigraphy and heart rate variation analysis, and check melatonin level as objective measurements. The investigators use delirium scales to evaluate delirium and its severity. The light therapy is stopped once a participant is diagnosed of delirium or transferred, and the investigators keep following participants until discharge to evaluate the prognosis.

03

Conditions studied

  • Circadian Dysrhythmia
  • Delirium

Browse trials for

Keywords

  • Circadian rhythm
  • ICU
  • Acute myocardial infarction
  • Delirium
  • Light therapy
04

Who can participate

Ages eligible
35 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis for admission is acute myocardial infarction with severity between Killip I-III.
  • Age is between 35-85.
  • Participants who are willing to participate in the study and sign the .

Exclusion criteria

Exclusion Criteria:

  • Using sedative hypnotic drugs.
  • Blindness or severe cataract.
  • Neurological diseases such as epilepsy, brain injury, or stroke.
  • Severe mental disorder such as major depressive disorder, bipolar disorder, schizophrenia, intellectual disability or substance use disorders.
  • Unable to communicate.
  • Participants who are unwilling to participate in the study or refuse to sign the .
  • Participants who are not suitable to include in this study, evaluate by PI or Co-PI.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
70 participants (estimated)

Study arms

  • Experimental
    Blue light therapy

    The participants receive blue light therapy for 1 hours, between 8am to 12pm in the morning.

    Device: Blue light therapy

  • Sham comparator
    White light

    The participants receive white light for 1 hour, between 8am to 12pm in the morning.

    Other: White light

Interventions

  • DeviceBlue light therapy

    Blue light therapy has been proved its efficacy and safety is treatment circadian rhythm disorder as well as other diseases.

  • OtherWhite light

    White light is used as sham control.

06

What researchers measure

Primary outcomes

  1. Changes of the circadian rhythm during admission by actigraphy

    Actigraphy data

    Time frame: an average of 2 weeks of continuous monitoring since baseline till discharge, up to 4 weeks

  2. Changes of the circadian rhythm during admission by heart-rate-variation-analysis

    heart-rate-variation-analysis data

    Time frame: baseline for 48hours, and 24hours before discharge

  3. Changes of Melatonin level

    Melatonin level

    Time frame: collect saliva in the morning and at the night of Day 1 and the day of discharge

  4. Changes of Vitamin D level

    Vitamin D level

    Time frame: blood sampling at Day 1 and the day of discharge

Secondary outcomes

  1. Confusion Assessment Method for the Intensive Care Unit

    Evaluation of delirium and its severity, score range 0-7, and score 0-2 no delirium, 3-5 mild to moderate, 6-7 severe

    Time frame: evaluate daily since baseline to discharge, for an average of 2 weeks, up to 4 weeks

  2. Intensive Care Delirium Screen Checklist

    Evaluation of delirium and its severity, score range 0-8, and score 4-8 suspected delirium

    Time frame: evaluate daily since baseline to discharge, for an average of 2 weeks, up to 4 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Salluh JI, Wang H, Schneider EB, Nagaraja N, Yenokyan G, Damluji A, Serafim RB, Stevens RD. Outcome of delirium in critically ill patients: systematic review and meta-analysis. BMJ. 2015 Jun 3;350:h2538. doi: 10.1136/bmj.h2538. PubMed 26041151 ↗
  • van Maanen A, Meijer AM, van der Heijden KB, Oort FJ. The effects of light therapy on sleep problems: A systematic review and meta-analysis. Sleep Med Rev. 2016 Oct;29:52-62. doi: 10.1016/j.smrv.2015.08.009. Epub 2015 Sep 9. PubMed 26606319 ↗
  • Ono H, Taguchi T, Kido Y, Fujino Y, Doki Y. The usefulness of bright light therapy for patients after oesophagectomy. Intensive Crit Care Nurs. 2011 Jun;27(3):158-66. doi: 10.1016/j.iccn.2011.03.003. Epub 2011 Apr 21. PubMed 21511473 ↗
  • Taguchi T, Yano M, Kido Y. Influence of bright light therapy on postoperative patients: a pilot study. Intensive Crit Care Nurs. 2007 Oct;23(5):289-97. doi: 10.1016/j.iccn.2007.04.004. Epub 2007 Aug 9. PubMed 17692522 ↗
  • Oh J, Cho D, Park J, Na SH, Kim J, Heo J, Shin CS, Kim JJ, Park JY, Lee B. Prediction and early detection of delirium in the intensive care unit by using heart rate variability and machine learning. Physiol Meas. 2018 Mar 27;39(3):035004. doi: 10.1088/1361-6579/aaab07. PubMed 29376502 ↗
  • Osse RJ, Tulen JH, Hengeveld MW, Bogers AJ. Screening methods for delirium: early diagnosis by means of objective quantification of motor activity patterns using wrist-actigraphy. Interact Cardiovasc Thorac Surg. 2009 Mar;8(3):344-8; discussion 348. doi: 10.1510/icvts.2008.192278. Epub 2008 Dec 22. PubMed 19103609 ↗
  • Papaioannou VE, Maglaveras N, Houvarda I, Antoniadou E, Vretzakis G. Investigation of altered heart rate variability, nonlinear properties of heart rate signals, and organ dysfunction longitudinally over time in intensive care unit patients. J Crit Care. 2006 Mar;21(1):95-103; discussion 103-4. doi: 10.1016/j.jcrc.2005.12.007. PubMed 16616632 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2021 (actual). Primary completion is estimated for Aug 2024, 39 months after the start.

Of 219 non-industry interventional studies with no phase under Delirium, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 45. This study's planned 39 months is above that.

Counting every sponsor, half of 222 studies reached it within 26 months; a quarter within 12 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 21, 2021
First posted
Jul 8, 2021
StartActual
May 12, 2021
Primary completionEst.
Aug 31, 2024
CompletionEst.
Aug 31, 2024
Last update
Aug 30, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 30, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04953767
Responsible party
Sponsor
First posted
Jul 8, 2021
Start date
May 12, 2021
Primary completion
Aug 31, 2024 (estimated)
Completion
Aug 31, 2024 (estimated)
Last update
Aug 30, 2023

Study contacts

Wei-Chih Chin
Contact
auaug0327@cgmh.org.tw
+886 3 3281200 ext. 3836
Wei-Chih Chin
principal investigator · Chang Gung Medical Foundation

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion